RecruitingPhase 2NCT04485286

Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury

Sponsor

Massachusetts General Hospital

Enrollment

72 participants

Start Date

Jul 19, 2020

Study Type

INTERVENTIONAL

Conditions

Lung Cancer Pancreas Cancer Radiation Fibrosis Radiation Induced Lung Injury

Summary

The goal of this study is to investigate the efficacy of \[68Ga\]CBP8 to detect collagen deposition in radiation induced tissue injury.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study evaluates a new PET scan imaging agent called [68Ga]CBP8 that may be able to detect radiation-related tissue damage in the lungs or pancreas — helping doctors identify which patients are developing serious side effects from radiation treatment before symptoms become severe. **You may be eligible if...** - You have non-small cell lung cancer (stage I–III) and are receiving or have received radiation therapy - You have pancreatic cancer and are receiving or have received radiation therapy - You are 18 or older and have not smoked in the past 6 months - You have a life expectancy greater than 3 months **You may NOT be eligible if...** - You are a current smoker - You are pregnant or breastfeeding - You have conditions that would make PET scanning unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[68Ga]CBP8

Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject. Each subject will undergo baseline imaging prior to radiation and again 3-6 months after radiation therapy.